|Title:||Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update||Authors:||Sarin S.K.
Al Mahtab M.
|Issue Date:||2016||Publisher:||Springer||Journal Volume:||10||Journal Issue:||1||Start page/Pages:||1-98||Source:||Hepatology International||Abstract:||
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts’ personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information. ? 2015, The Author(s).
|ISSN:||1936-0533||DOI:||10.1007/s12072-015-9675-4||SDG/Keyword:||adefovir dipivoxil; alanine aminotransferase; clevudine; cyclopentane derivative; entecavir; hepatitis B(e) antigen; lamivudine; peginterferon alpha; RNA directed DNA polymerase inhibitor; telbivudine; tenofovir alafenamide; tenofovir disoproxil; virus vaccine; antivirus agent; adaptive immunity; age distribution; alanine aminotransferase blood level; Asian; chronic hepatitis B; clinical practice; combination chemotherapy; controlled clinical trial (topic); cryoglobulinemia; disease association; disease exacerbation; drug choice; Editorial; geographic distribution; glomerulonephritis; Guillain Barre syndrome; hepatitis B; human; Human immunodeficiency virus infection; immunological tolerance; immunoreactivity; incidence; infection prevention; infection risk; innate immunity; kidney failure; liver disease; liver stiffness; liver transplantation; medical history; medical terminology; mixed infection; monotherapy; multicenter study (topic); nonhuman; patient assessment; patient counseling; personal experience; polyarteritis nodosa; practice guideline; predictive value; pregnancy; prevalence; priority journal; public health; public health problem; publication; risk assessment; screening; seroconversion; serum sickness; time to treatment; treatment duration; treatment indication; vaccination; vertical transmission; viral clearance; virus load; virus pathogenesis; virus reactivation; virus transmission; acute disease; Africa; Asia; disease management; female; hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; isolation and purification; male; practice guideline; Acute Disease; Africa; Antiviral Agents; Asia; Disease Management; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male
|Appears in Collections:||醫學教育暨生醫倫理學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.